Wall Street expects a year-over-year increase in earnings on higher revenues when Alpine Immune Sciences, Inc. (ALPN) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be relea ...

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Thursday, February 8th, the Company will participate in a fireside chat at 10:00 am ET/7:00 am PT during the Guggenheim 6th Annual Biotechnology Conference in New York, NY and host investor meetings the same day. W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8969493 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8969493 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37449 ALPINE IMMUNE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8969493 (State or other j ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Paul Rickey - CFO Conference Call Participants Mike Ulz - Morgan Stanley Tara Bancroft - Cowen Mark Breidenbach - Oppenheimer Joe Pantginis - H.C. Wainwright Operator Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call. Currently, all participants are in listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 Registrant's telephone number, including area code: (206) 788-4545 Securities registered pursuant to Section 12(b) of the Act: | --- | --- ...

Leading the Next Evolution of Immunotherapies March 2023 Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section27A of the Securities Act of 1933, Section21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based onhistorical fact and include statements regarding Alpine’s platform technology, potential therapies, potential milestone and royalty payments, futuredevel ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Andrew Sandler - CMO Paul Rickey - CFO Operator Welcome to the Alpine Immune Sciences Third Quarter Earnings Call. Currently all participants are in a listen-only mode. As a reminder, this event is being recorded. I would now like to introduce Temre Johnson, Senior Director of Invest ...